Curing Autism, Epilepsy & Schizophrenia with Stem Cells | Dr. Sergiu Pașca

In this episode, Dr. Andrew Huberman speaks with Dr. Sergiu Pașca about groundbreaking advances in understanding and treating autism spectrum disorder, epilepsy, and schizophrenia through stem cell research. Dr. Pașca begins by addressing the apparent increase in autism diagnoses, explaining that while genuine increases exist, much of the rise reflects improved recognition, expanded diagnostic criteria, and increased awareness among parents and healthcare providers. He emphasizes that autism is fundamentally a difference in brain development and function rather than a defect, with significant genetic contributions to susceptibility.

The conversation explores the biology of autism, including why males are diagnosed more frequently than females. Dr. Pașca discusses how early developmental markers like eye contact and responses to fever may indicate neurobiological differences associated with autism. The discussion then shifts to the distinction between genetic and idiopathic autism diagnoses, including specific examples like Timothy Syndrome, a rare genetic condition that frequently presents with autism as a phenotype.

A major focus of the episode involves Dr. Pașca's pioneering work with organoids and assembloids. These are human stem cell-derived three-dimensional structures that recapitulate aspects of human brain development and organization. Unlike traditional animal models, organoids allow researchers to study distinctly human brain characteristics in controlled laboratory settings. Assembloids take this further by combining different brain region-specific organoids to model interactions between brain areas, more closely mimicking the complexity of intact neural circuits.

Dr. Pașca explains how stem cell technology enables personalized medicine approaches. By reprogramming patient cells into stem cells and then differentiating them into specific brain cell types, researchers can create disease models that reflect individual genetic backgrounds. This allows investigation of how specific genetic mutations contribute to neurological conditions and testing of potential therapeutic interventions on patient-derived cells before moving to clinical trials.

The episode addresses significant ethical and practical considerations surrounding gene editing and stem cell therapies in humans. Dr. Pașca discusses safety concerns, the importance of long-term follow-up studies, and the need for careful ethical frameworks as these technologies advance. He emphasizes that while these approaches hold tremendous promise for understanding and potentially curing severe neurological conditions, responsible development requires addressing concerns about off-target effects, immunological responses, and long-term outcomes.

Throughout the conversation, Dr. Pașca conveys both the excitement and responsibility associated with his work. He discusses how understanding the fundamental biology of autism and other psychiatric conditions through advanced cellular models could lead to interventions that address root causes rather than merely managing symptoms. The research suggests that many cases of profound autism may eventually become treatable or curable through targeted interventions based on individual genetic and developmental profiles.